Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
YL-13027 by Shanghai Yingli Pharmaceutical for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
YL-13027 is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas....
Data Insights
YL-13027 by Shanghai Yingli Pharmaceutical for Solid Tumor: Likelihood of Approval
YL-13027 is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase I for Solid Tumor. According to GlobalData,...